Comment on: Real-life effectiveness of canakinumab in cryoprin-associated periodic syndrome

Rheumatology (Oxford). 2016 Jul;55(7):1340-1. doi: 10.1093/rheumatology/kew234. Epub 2016 May 17.

Authors

Guido Junge¹, Uwe Machein²

Affiliations

¹ Immunology and Dermatology Novartis Pharma AG Basel, Global Medical Affairs, Switzerland.
² Immunology and Dermatology Novartis Pharma AG Basel, Global Medical Affairs, Switzerland uwe.machein@novartis.com.

PMID: 27190226
DOI: 10.1093/rheumatology/kew234

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Cryopyrin-Associated Periodic Syndromes*
Humans
Interleukin-1beta

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Interleukin-1beta
canakinumab